Does TAFASITAMAB Cause Diffuse large b-cell lymphoma? 346 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 346 reports of Diffuse large b-cell lymphoma have been filed in association with TAFASITAMAB (MONJUVI). This represents 24.9% of all adverse event reports for TAFASITAMAB.
346
Reports of Diffuse large b-cell lymphoma with TAFASITAMAB
24.9%
of all TAFASITAMAB reports
206
Deaths
37
Hospitalizations
How Dangerous Is Diffuse large b-cell lymphoma From TAFASITAMAB?
Of the 346 reports, 206 (59.5%) resulted in death, 37 (10.7%) required hospitalization, and 5 (1.4%) were considered life-threatening.
Is Diffuse large b-cell lymphoma Listed in the Official Label?
Yes, Diffuse large b-cell lymphoma is listed as a known adverse reaction in the official FDA drug label for TAFASITAMAB.
What Other Side Effects Does TAFASITAMAB Cause?
Disease progression (470)
Off label use (203)
Death (146)
Neutropenia (99)
Covid-19 (96)
General physical health deterioration (75)
Pneumonia (66)
Febrile neutropenia (64)
Drug ineffective (62)
Thrombocytopenia (60)
What Other Drugs Cause Diffuse large b-cell lymphoma?
RITUXIMAB (1,571)
CYCLOPHOSPHAMIDE (1,183)
PREDNISONE (1,062)
METHOTREXATE (1,055)
VINCRISTINE (1,043)
DOXORUBICIN (1,002)
LENALIDOMIDE (779)
TACROLIMUS (595)
DEXAMETHASONE (539)
PREDNISOLONE (506)
Which TAFASITAMAB Alternatives Have Lower Diffuse large b-cell lymphoma Risk?
TAFASITAMAB vs TAFASITAMAB-CXIX
TAFASITAMAB vs TAFINLAR
TAFASITAMAB vs TAFLUPROST
TAFASITAMAB vs TAGRAXOFUSP-ERZS
TAFASITAMAB vs TAHOR